We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COPD on Primary Care Treatment (COOPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00184977
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : March 12, 2010
Sponsor:
Collaborators:
Dutch Health Care Insurance Board (CVZ)
GlaxoSmithKline
Zambon SpA
The Netherlands Asthma Foundation
Information provided by:
Radboud University Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this family practice based study is to determine the long-term treatment effects of two drugs that are presumed to modify the course and progression of chronic obstructive pulmonary disease (COPD), oral N-acetylcysteine and inhaled corticosteroids.

Condition or disease Intervention/treatment Phase
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Bronchitis, Chronic Drug: N-acetylcysteine Drug: fluticasone propionate Phase 4

Detailed Description:

Chronic obstructive pulmonary disease (COPD) is a disorder characterised by symptoms and abnormal tests of expiratory flow that do not change markedly over periods of several months observation. COPD includes chronic bronchitis and emphysema. It is not fully clear which medication is the most efficacious in the long-term treatment of COPD. In contrast to asthma, the efficacy and therefore the precise role of inhaled corticosteroids is less clear in the treatment of patients with COPD. The same applies to another (much less investigated) possibility in the treatment of COPD, the anti-oxidant agent N-acetylcysteine. N-acetylcysteine is used as a mucolytic agent in a variety of clinical conditions, such as acute and chronic bronchitis and cystic fibrosis. The aim of this study, which is performed in family practices, is to determine the 3-year treatment effects and cost-effectiveness of oral N-acetylcysteine versus an inhaled corticosteroid (fluticason propionate) in modifying the course and progression of COPD.

Comparisons: N-acetylcysteine (oral, 600 mg o.d.) and fluticason propionate (dry powder inhalation, 500 mcg b.i.d.) are compared with placebo

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-blind Placebo-controlled Trial Comparing the Efficacy and Cost-effectiveness of Inhaled Fluticason Propionate Versus Oral N-acetylcysteine in the Treatment of Patients With COPD in General Practice
Study Start Date : December 1998
Study Completion Date : January 2003

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. exacerbations of COPD, condition-specific quality of life

Secondary Outcome Measures :
  1. lung function decline, respiratory symptoms

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age between 30 and 75 years
  • being a smoker or ex-smoker
  • post-bronchodilator FEV1/FVC ratio is <88% of the predicted value in case of men or <89% of the predicted value in case of women
  • post-bronchodilator FEV1>=40% and <90% of the predicted value
  • subjects have a GP diagnosis of COPD or had increased cough, sputum and/or dyspnea on most days for 3 or more months a year, for at least the last 2 years
  • able to provide a written informed consent
  • expected to be able to comply with the study protocol
  • able to communicate with the study personnel and to understand and read instructions
  • females of childbearing potential should use an acceptable method for birth control

Exclusion Criteria:

  • a known history of intolerance or allergy for N-acetylcysteine or fluticason
  • use of long-term oxygen therapy or expected to be in need of oxygen therapy within the next 3 years
  • registered asthma, allergic rhinitis, and/or allergic eczema as an active problem in the GPs records within the last 12 months
  • alpha1-antitrypsin deficiency
  • cystic fibrosis
  • active infection due to Mycobacterium tuberculosis
  • status post-lobectomy
  • clinically proven gastric or duodenal ulcer in the previous six months
  • non-compensated severe chronic congestive heart failure
  • life expectancy reduction (e.g. malignancies)
  • evidence of illicit drug use or abuse of alcohol intake
  • expected not to be compliant in taking medications in general
  • being pregnant or giving breastfeeding
  • not complying with the inclusion criteria
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184977


Locations
Layout table for location information
Netherlands
Department of Family Medicine, University of Maastricht
Maastricht, Netherlands, 6200 MD
Department of Family Medicine, Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University Medical Center
Dutch Health Care Insurance Board (CVZ)
GlaxoSmithKline
Zambon SpA
The Netherlands Asthma Foundation
Investigators
Layout table for investigator information
Principal Investigator: Tjard RJ Schermer, MSc, PhD Radboud University Nijmegen Medical Centre, Department of Family Medicine
Study Director: Chris van Weel, MD, PhD Radboud University Nijmegen Medical Centre, Department of Family Medicine
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00184977    
Other Study ID Numbers: 98-46140
95093 FLU9802 NAC-NL-11
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: March 12, 2010
Last Verified: August 2006
Keywords provided by Radboud University Medical Center:
Pulmonary Disease, Chronic Obstructive
Randomized Controlled Trial
Family Practice
Respiratory Function Tests
Health Status
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchitis
Bronchitis, Chronic
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Respiratory Tract Infections
Infections
Bronchial Diseases
Fluticasone
Xhance
Acetylcysteine
 N-monoacetylcystine
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Antiviral Agents
Anti-Infective Agents
Expectorants
Free Radical Scavengers
Antioxidants